Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (61-70 of 205) with videos related to

Pageof 21
Sort By:
Molecular Cancer Therapeutics|May 7, 2020
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal TumorAlfonso García-Valverde, Jordi Rosell, Garazi Serna, et al.
Molecular & Cellular Proteomics : MCP|February 6, 2004
Targeted therapy in breast cancer: the HER-2/neu gene and proteinJeffrey S Ross, Jonathan A Fletcher, Kenneth J Bloom, et al.
Oncogene|March 10, 2004
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)Anette Duensing, Fabiola Medeiros, Bryna McConarty, et al.
The American Journal of Surgical Pathology|June 30, 2004
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implicationsFabiola Medeiros, Christopher L Corless, Anette Duensing, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcomaMiriam Lynn, Yuexiang Wang, Jaime Slater, et al.
Cancer Research|October 3, 2007
Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumorsKatherine A Janeway, Bernadette Liegl, Amy Harlow, et al.
The Oncologist|August 5, 2003
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapyJeffrey S Ross, Jonathan A Fletcher, Gerald P Linette, et al.
The American Journal of Surgical Pathology|April 5, 2014
VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?Nathaniel E Smith, Andrea T Deyrup, Adrian Mariño-Enriquez, et al.
Oncotarget|February 27, 2016
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaRobert Nakayama, Yi-Xiang Zhang, Jeffrey T Czaplinski, et al.
Oncotarget|April 30, 2016
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3Peipei Yang, Weicai Chen, Xuhui Li, et al.
Pageof 21

Showing results (61-70 of 205) with videos related to

Sort By:
Pageof 21
Molecular Cancer Therapeutics|May 7, 2020
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal TumorAlfonso García-Valverde, Jordi Rosell, Garazi Serna, et al.
Molecular & Cellular Proteomics : MCP|February 6, 2004
Targeted therapy in breast cancer: the HER-2/neu gene and proteinJeffrey S Ross, Jonathan A Fletcher, Kenneth J Bloom, et al.
Oncogene|March 10, 2004
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)Anette Duensing, Fabiola Medeiros, Bryna McConarty, et al.
The American Journal of Surgical Pathology|June 30, 2004
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implicationsFabiola Medeiros, Christopher L Corless, Anette Duensing, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcomaMiriam Lynn, Yuexiang Wang, Jaime Slater, et al.
Cancer Research|October 3, 2007
Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumorsKatherine A Janeway, Bernadette Liegl, Amy Harlow, et al.
The Oncologist|August 5, 2003
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapyJeffrey S Ross, Jonathan A Fletcher, Gerald P Linette, et al.
The American Journal of Surgical Pathology|April 5, 2014
VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?Nathaniel E Smith, Andrea T Deyrup, Adrian Mariño-Enriquez, et al.
Oncotarget|February 27, 2016
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaRobert Nakayama, Yi-Xiang Zhang, Jeffrey T Czaplinski, et al.
Oncotarget|April 30, 2016
Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3Peipei Yang, Weicai Chen, Xuhui Li, et al.
Pageof 21